Overview

Ipilimumab Yervoy is almost never sourced alone; its demand is tied to combination protocols with nivolumab, which makes supply planning a coordination problem more than a single-product order. This article covers the B2B sourcing and cold-chain realities that distributors must manage for this CTLA-4 inhibitor.

How It Works

Ipilimumab is a monoclonal antibody that blocks CTLA-4, a checkpoint expressed on naive and regulatory T cells. By occupying CTLA-4, it frees co-stimulatory signals in lymphoid tissue, broadening the early priming of anti-tumor T-cell responses. In combination with PD-1 blockade, the two checkpoints are hit at different stages of immune activation, producing deeper and more durable responses than either alone in eligible tumors.

Indications

Indications include adjuvant and unresectable melanoma, and combination use in renal-cell carcinoma and microsatellite-stable colorectal cancer per local approvals. It is given for a defined limited course, often four doses with nivolumab, rather than indefinitely. Combination eligibility and immune-related toxicity monitoring govern where and how it is used.

Dosage & Administration

Typical regimens use 1 mg/kg or 3 mg/kg with nivolumab intravenously every three weeks for four doses. Infusion occurs in a facility prepared for immune-related adverse events. Because the course is short and fixed, sourcing should be planned as a bundled combo pack with the partner product to avoid mismatched delivery dates.

The four-dose plan should be mapped on a calendar with the partner product so both vials arrive before each infusion appointment.

Storage & Sourcing

Vials must be stored at 2 to 8 °C, protected from light, and never frozen; maintain the cold chain from receipt to ward. For buyers, the key is synchronizing Ipilimumab and Nivolumab deliveries and confirming each vial's remaining in-use window after dilution. Request GMP and batch documentation, and reject any unit with a broken cold-chain record.

Log every transfer from cold storage to ward, since the limited course leaves little slack for a rejected, excursion-exposed vial.

FAQ

Q: How should a distributor handle combo sourcing with Nivolumab? A: Plan both products as one combined order on the three-week cadence so the four-dose course is never delayed by a missing partner vial.

Q: What cold-chain evidence is required at receiving? A: Verify the 2 to 8 °C logger, light protection, and unbroken seals; any freeze exposure or excursion should trigger rejection per protocol.

Q: Is there a fixed course length that aids forecasting? A: Yes, the limited four-dose schedule makes demand predictable in patient numbers, helping buyers size combo packs without large safety stock.